Cardioprotective glucose-lowering drugs, statins, and secondary major adverse cardiovascular events: a nationwide cohort study of individuals with type 2 diabetes and cardiovascular disease
Tummas Ternhamar, Mia Ø Johansen, Børge G Nordestgaard, Shoaib Afzal · 2026
Read Cardioprotective glucose-lowering drugs, statins, and secondary major adverse cardiovascular events: a nationwide cohort study of individuals with type 2 diabetes and cardiovascular disease by Tummas Ternhamar, Mia Ø Johansen, Børge G Nordestgaard, Shoaib Afzal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13501814.txt.
Description
Tummas Ternhamar leads a four-author team reporting a 2026 nationwide Danish cohort study of drug combinations after cardiovascular disease in type 2 diabetes. Two drug families protect the heart: modern glucose-lowering agents and statins. No trial can ethically test withholding statins, so registers covering December 2012 to 2021 supplied the data. An active comparator cohort held 15,404 people starting a new glucose drug, and a time-varying cohort held 76,853 people with yearly updated treatment status.
Combined therapy beat either drug alone. Against people on neither treatment, the combination carried a hazard ratio of 0.71 for a new major cardiovascular event in the active comparator cohort and 0.57 in the time-varying cohort on those analyses. Single-drug groups sat in between, and no statistical interaction appeared between the two drug classes. The authors note real-world prescribing still underuses both, though they caution that register data can never fully exclude bias.
Catalog record
| CREATOR | Tummas Ternhamar, Mia Ø Johansen, Børge G Nordestgaard, Shoaib Afzal |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60536 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |